I am surprised AXON trading at nearly $1.5B market cap on a pretty failed (in previous trials) Alz drug candidate from Glaxo that AXON bought at $5M only. Good to see AXON tanking daily, was at $31 in June 2015 on IPO day, now trading on $12.90. I guess AXON should be at $1.50 while AVXL should be at $15. Nice trend here in AVXL...looks like a winner. glta
very true. IPO targeted to complete phase-3, end of Q1 2015 $70M cash on hand, 13M o/s, 4M float, two phase-3 initiated abCONTOUR1, abCONTOUR2, 1600 patients to enroll, top line data end of this year. I got fed up with many bio that do dilution several times and live in penny land, I see massive upside in this one.